Antisense drug for PCARP disease caused by FLVCR1 mutation
Part of Brain & nervous system, Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new drug called an antisense oligonucleotide (a type of genetic medicine) for people with a specific form of inherited eye disease called PCARP, which is caused by changes in the FLVCR1 gene. The goal is to see if the drug can slow or stop vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic mutation in the FLVCR1 gene.
- You must be able to travel to the study site and keep all follow-up appointments.
- You must not be allergic to any part of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational RNA therapy called sepofarsen for people with Leber Congenital Amaurosis (LCA) type 10, a rare inherited eye disease that causes severe vision loss from birth. The goal is to see if it can slow or improve vision loss.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This trial tests a new medicine called PYC-001, given as an injection into the eye, for people with a specific genetic form of vision loss called autosomal dominant optic atrophy (ADOA). It aims to see if the treatment is safe and could help protect or improve vision.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This study tests a new cell therapy (OpCT-001) for adults with inherited retinal diseases that affect the light-sensing cells. It aims to see if the treatment is safe and possibly helps improve vision.
Hear when a new Posterior Column Ataxia With Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.